Jefferies Adjusts HealthEquity Price Target to $95 From $79, Maintains Buy Rating
Jefferies Keeps Their Buy Rating on Healthequity (HQY)
Buy Rating on Healthequity (HQY) Affirmed Amid HSA Market Growth and Competitive Outperformance
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Aerovate Therapeutics (AVTE) and Delcath Systems (DCTH)
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Healthequity (HQY) and Bluebird Bio (BLUE)
HealthEquity Analyst Ratings
HealthEquity Outperforms With Strong Quarterly Results and Positive Fiscal 2025 Outlook: Buy Rating Reaffirmed
Analysts' Top Healthcare Picks: Healthequity (HQY), Exscientia Plc (EXAI)
RBC Raises Price Target on HealthEquity to $92 From $90, Notes Fiscal Q4 Results at High End of Preannounced Ranges; Outperform Kept
Healthequity (HQY) Receives a Buy From RBC Capital
HealthEquity Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Shockwave Medical (SWAV) and Healthequity (HQY)
Barclays Keeps Their Buy Rating on Healthequity (HQY)
HealthEquity (HQY) Poised for Strong Growth and Resilience, Earns 'Buy' Rating
Healthequity's Financial Growth and Strategic Asset Management Shift Justify a Buy Rating
HealthEquity Analyst Ratings
RBC Raises Price Target on HealthEquity to $90 From $77, Keeps Outperform Rating
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), Insulet (PODD) and Healthequity (HQY)
Buy Rating Affirmed for HealthEquity: A Path to Doubling EPS Through Strategic Growth and Innovation
Barclays Sticks to Its Buy Rating for Healthequity (HQY)
No Data